Sugi Predict

Sugi Predict / Compounds / SCHEMBL587558

SCHEMBL587558

SCHEMBL587558

CC1(C)OB(c2cc(F)c(Cl)c(F)c2)OC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 13/20 0.47
▸ LIPG Q9Y5X9 13/20 0.47
▸ EGFR P00533 1/20 0.38
▸ ROCK1 Q13464 1/20 0.37
▸ CA1 P00915 3/20 0.34
▸ CA2 P00918 3/20 0.34
▸ CA9 Q16790 3/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA3 P07451 1/20 0.34
▸ CA4 P22748 1/20 0.34
▸ CA6 P23280 1/20 0.34
▸ CA5A P35218 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ CA5B Q9Y2D0 1/20 0.34
▸ F11 P03951 1/20 0.33
▸ P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14956207 0.91 LPL (0.43) LPLLIPGEGFRROCK1CA1
SCHEMBL16296696 0.89 LPL (0.42) LPLLIPGEGFRROCK1CA1
SCHEMBL6691092 0.83 LPL (0.50) LPLLIPGROCK1CA1CA2
SCHEMBL14956694 0.83 LPL (0.43) LPLLIPGEGFRROCK1CA1
SCHEMBL16962901 0.82 ROCK1 (0.39) LPLLIPGEGFRROCK1CA1
SCHEMBL16535308 0.82 LPL (0.42) LPLLIPGEGFRROCK1CA1
SCHEMBL26153570 0.82 LPL (0.48) LPLLIPGEGFRROCK1CA1
SCHEMBL19510943 0.80 LPL (0.41) LPLLIPGEGFRROCK1CA1
SCHEMBL530239 0.80 LPL (0.41) LPLLIPGEGFRROCK1CA1
SCHEMBL59540 0.80 LPL (0.47) LPLLIPGROCK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 ASTRAZENECA AB (SE) 2025-09-02 — — US disclosed
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-11-21 — — US disclosed
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 ASTRAZENECA AB (SE) 2024-06-20 — — US disclosed
WO-2023177667-A1 THYROID HORMONE RECEPTOR AGONISTS BRII BIOSCIENCES, INC. (US) 2023-09-21 — — WO disclosed
CN-108558871-B Tricyclic compounds as anticancer agents 百时美施贵宝公司 2022-02-18 — — CN disclosed
EP-3466949-A1 TRICYCLIC COMPOUND AS ANTICANCER AGENTS Bristol-Myers Squibb Company (US) 2019-04-10 — — EP disclosed
US-10112941-B2 Tricyclic compounds as anticancer agents BRISTOL-MYERS SQUIBB COMPANY (US) 2018-10-30 — — US disclosed
EP-3087071-B1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS BRISTOL MYERS SQUIBB CO (US) 2018-09-05 — — EP disclosed
US-20170327498-A1 NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS BRISTOL MYERS SQUIBB CO (US) 2017-11-16 — — US disclosed
US-9751879-B2 Tricyclic compounds as anticancer agents BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-05 — — US disclosed
US-20160318928-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS BRISTOL MYERS SQUIBB CO (US) 2016-11-03 — — US disclosed
EP-3087071-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS Bristol-Myers Squibb Company (US) 2016-11-02 — — EP disclosed
CN-106029663-A Tricyclic compounds as anticancer agents 百时美施贵宝公司 2016-10-12 — — CN disclosed
US-9458156-B2 Tricyclic compounds as anticancer agents BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-04 — — US disclosed
US-20160176864-A1 NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS BRISTOL-MYERS SQUIBB COMPANY 2016-06-23 — — US disclosed
WO-2015100282-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-07-02 — — WO disclosed
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 — — US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 — — EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 — — WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199558-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 LPL 3026/4885LIPG 2773/4885EGFR 3178/4885
US-20240383866-A1 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 CX3CR1, CCR2, CCR5 LPL 3026/4885LIPG 2773/4885EGFR 3178/4885
US-20160318928-A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS TP53, TK2, TOP2A LPL 3105/4885LIPG 2323/4885EGFR 1009/4885
US-12404253-B2 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 CX3CR1, CCR2, CCR5 LPL 3026/4885LIPG 2773/4885EGFR 3178/4885
US-20160176864-A1 NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS TP53, TK2, MCL1 LPL 3441/4885LIPG 2597/4885EGFR 1180/4885
US-10112941-B2 Tricyclic compounds as anticancer agents TP53, TK2, TOP2A LPL 3181/4885LIPG 2640/4885EGFR 762/4885
US-20170327498-A1 NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS TP53, TK2, MCL1 LPL 3441/4885LIPG 2597/4885EGFR 1180/4885
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 LPL 4511/4885LIPG 4757/4885EGFR 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.